Teva Pharmaceutical Industries (NYSE:TEVA) Given New $20.00 Price Target at Barclays

Teva Pharmaceutical Industries (NYSE:TEVA - Free Report) had its target price hoisted by Barclays from $17.00 to $20.00 in a research note published on Thursday, Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms have also recently weighed in on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a report on Thursday, February 1st. The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a neutral rating in a report on Monday, February 5th. Piper Sandler raised shares of Teva Pharmaceutical Industries from a neutral rating to an overweight rating and upped their target price for the company from $12.00 to $19.00 in a report on Monday, February 12th. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and upped their target price for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an underweight rating to a neutral rating and set a $14.00 target price for the company in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $14.11.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.27 during mid-day trading on Thursday, hitting $16.01. 16,779,394 shares of the company traded hands, compared to its average volume of 10,858,707. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The stock has a 50-day moving average price of $13.70 and a two-hundred day moving average price of $11.72. Teva Pharmaceutical Industries has a 1 year low of $7.09 and a 1 year high of $16.25. The stock has a market cap of $17.95 billion, a price-to-earnings ratio of -34.06, a P/E/G ratio of 1.67 and a beta of 1.04.

Insider Transactions at Teva Pharmaceutical Industries

In other news, VP Eric Drape sold 9,815 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total value of $128,772.80. Following the completion of the sale, the vice president now directly owns 9,701 shares of the company's stock, valued at $127,277.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Richard D. Francis sold 74,530 shares of the company's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Eric Drape sold 9,815 shares of the company's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $13.12, for a total transaction of $128,772.80. Following the transaction, the vice president now owns 9,701 shares of the company's stock, valued at approximately $127,277.12. The disclosure for this sale can be found here. Insiders sold a total of 358,972 shares of company stock valued at $4,739,820 over the last three months. Corporate insiders own 0.55% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Teva Pharmaceutical Industries by 36.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,691 shares of the company's stock valued at $8,857,000 after purchasing an additional 167,097 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in Teva Pharmaceutical Industries by 13.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,018 shares of the company's stock valued at $875,000 after purchasing an additional 7,335 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its position in Teva Pharmaceutical Industries by 4.0% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company's stock valued at $346,000 after purchasing an additional 947 shares during the last quarter. QRG Capital Management Inc. lifted its position in Teva Pharmaceutical Industries by 53.7% during the first quarter. QRG Capital Management Inc. now owns 143,747 shares of the company's stock valued at $2,028,000 after purchasing an additional 50,247 shares during the last quarter. Finally, Headlands Technologies LLC lifted its position in Teva Pharmaceutical Industries by 339.4% during the first quarter. Headlands Technologies LLC now owns 15,206 shares of the company's stock valued at $215,000 after purchasing an additional 11,745 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.